Cannabis Law Report

SEPTEMBER 13, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021. in the blood. About MyMD Pharmaceuticals, Inc.

Clinical Trials 52

Clinical Trials Pharmaceutical Research and Development Therapy 52

Cannabis Law Report

NOVEMBER 15, 2021

a manufacturer of LinearDNA™ via PCR for nucleic acid therapeutics and diagnostics, today announced the receipt of repeat orders from diagnostic customers and a first Contract Research Organization (CRO) order from a new biotherapeutic customer, a federally funded research and development laboratory focused on cancer research.

Research and Development 52

Research and Development Therapy Clinical Trials Supply Chain 52

Cannabis Law Report

NOVEMBER 16, 2021

As cleared by the FDA, the primary endpoint of the Phase 2 double-blind, placebo-controlled clinical trial is to achieve a reduction in the circulating levels of tumor necrosis factor-alpha (TNF-?), MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-? About MYMD-1.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

JUNE 25, 2021

billion in 2025 at a CAGR of 14%. This acquisition would also help Bristol-Myers Squibb to expedite the development of new innovative drugs which are in the early stages of drug pipeline. Celgene is an innovative biotechnology company that manufactures and develops cancer drugs. Cancer Research Centers. Chemotherapy.

Research and Development 84

Research and Development Therapy Pharmaceutical Clinical Trials 84

Cannabis Law Report

DECEMBER 23, 2021

Research on the endocannabinoid system is one of the most promising avenues for new therapeutics in medicine at the moment. billion by 2025. Research on the endocannabinoid system is one of the most promising avenues for new therapeutics in medicine at the moment. However, regulations are constantly shifting.

Pharmaceutical 96

Pharmaceutical Clinical Trials Research and Development Cannabinoids 96

SMPL

MAY 26, 2020

For years, he’d been determined to connect the nascent CBD research he heard about at symposiums abroad with the medical marijuana movement in California. CBD industry will be worth $16 billion by 2025. This makes further research very difficult to do, and causes sick people in many states to be treated as criminals.

CBD 40

CBD Research and Development Pharmaceutical Seed-To-Sale 40

Cannabis Law Report

JULY 15, 2022

Last week, federal Health Minister Greg Hunt announced changes to regulations that would allow for medicinal cannabis exports, capitalising on what the Government estimated would be a $70 billion industry by 2025. I know that Medifarm was the first fully licensed, so cultivation and manufacturing and research licensed company in Australia.

Medicine 52

Medicine Patients Media Supply Chain 52